‘Art of the Brain’ Raises Funds for Brain Cancer Research at UCLA

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 9
Volume 10
Issue 9

LOS ANGELES-Diagnosed with a life-threatening brain tumor 8 years ago, Mario del Valle chose not to be physically defeated. His artist mother, Pilar del Valle, helped inspire him to learn to use his left hand. Mr. del Valle, born in Colombia and now living in Northridge, California, overcame vision and other obstacles to produce watercolors such as the two shown above. Mr. del Valle is a participant in the UCLA Neuro-Oncology Program’s Art of the Brain, which encourages brain cancer patients and their caregivers to use creativity to regain self-worth and personal power. Timothy Cloughsey, MD, is director of the UCLA Neuro-Oncology Program

LOS ANGELES—Diagnosed with a life-threatening brain tumor 8 years ago, Mario del Valle chose not to be physically defeated. His artist mother, Pilar del Valle, helped inspire him to learn to use his left hand. Mr. del Valle, born in Colombia and now living in Northridge, California, overcame vision and other obstacles to produce watercolors such as the two shown above. Mr. del Valle is a participant in the UCLA Neuro-Oncology Program’s Art of the Brain, which encourages brain cancer patients and their caregivers to use creativity to regain self-worth and personal power. Timothy Cloughsey, MD, is director of the UCLA Neuro-Oncology Program

Art of the Brain was founded by brain cancer survivor Judi Kaufman to raise funds for advanced brain cancer research. Last year, Art of the Brain sponsored a festival that featured art from brain cancer patients and their caregivers alongside the work of world-renowned artists. This year’s event, Music from the Heart (October 7), will showcase brain cancer patients in musical performances.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
The pediatric care wing of the Jack & Sheryl Morris Cancer Center is intended to accommodate the physical and emotional needs of younger patients with cancer.
Approximately 10% of patients discontinued treatment with avutometinib/defactinib due to toxicity in the phase 2 RAMP 201 trial.
Response rates appeared to be higher with avutometinib plus defactinib vs avutometinib alone in the phase 2 RAMP 201 study.